ClinicalTrials.gg
CompletedNCT07024862Updated Nov 5, 2026

Long-term Outcomes Among Patients With Programmed Death-ligand 1 <1% Metastatic Non-small Cell Lung Cancer Treated With First-line Nivolumab + Ipilimumab + 2 Cycles of Chemotherapy

An observational study in Metastatic Non-small Cell Lung Cancer, sponsored by Bristol-Myers Squibb. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Bristol-Myers Squibb · Observational

How we know · 5 judgments

Updated Nov 5, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
103
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 131 studies in Carcinoma, Non-Small-Cell Lung by Bristol-Myers Squibb — 21 open to participants now, 35 under way, 10 of them phase 3. Carcinoma, Non-Small-Cell Lung · Bristol-Myers Squibb.

Enrollment
18th of 21
103 · median 404
Started
2024
with 7 others
Observational
21 of 131
2 open now
Registered
117th of 131
by date

Among the 131 studies in Carcinoma, Non-Small-Cell Lung by Bristol-Myers Squibb, this one is the 18th largest by enrollment of the 21 observational ones that give a count, is one of 8 that started in 2024, is one of 21 observational ones, and was the 117th registered.

Carcinoma, Non-Small-Cell Lung

7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

21 of the 131 studies in Carcinoma, Non-Small-Cell Lung by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:

16 more — sign in →

By country, each count listing its studies:

All 21 open studies →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 131 studies in Carcinoma, Non-Small-Cell Lung by Bristol-Myers Squibb, or all of them as a file.
02

Study summary

The study will assess the long-term real-world outcomes among adults diagnosed with programmed death-ligand 1 (PD-L1) \<1% metastatic non-small cell lung cancer (mNSCLC) treated with first-line (1L) nivolumab + ipilimumab + 2 cycles of chemotherapy (NIC) in the US

03

Conditions studied

  • Metastatic Non-small Cell Lung Cancer

Keywords

  • Metastatic non-small cell lung cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population will include adults diagnosed with programmed death-ligand 1 (PD-L1) \<1% metastatic non-small cell lung cancer (NSCLC) and treated with 1L combination nivolumab, ipilimumab, and 2 cycles of platinum-doublet chemotherapy (NIC) in the US community oncology setting

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At least 18 years old at confirmed diagnosis with non-small cell lung cancer (NSCLC) (stage IV), squamous or non-squamous histology
  • Initiated (1L) combination nivolumab, ipilimumab, and 2 cycles of platinum-doublet chemotherapy (NIC) regimen between 01 January 2018 and 2 years prior to study launch
  • Tumor programmed death-ligand 1 () negative expression (i.e., PD-L1 \<1%)
  • No EGFR, ALK, or ROS1 genetic mutation (i.e., wild type)
  • Minimum of 6 months of follow-up after initiation of 1L NIC*

Exclusion criteria

Exclusion Criteria:

  • Any prior systemic therapy for non-small cell lung cancer (NSCLC)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
103 participants (actual)
Patient registry
No

Groups and cohorts

  • Cohort 1

    Adults diagnosed with programmed death-ligand 1 (PD-L1) \<1% metastatic non-small cell lung cancer (mNSCLC) treated with first-line (1L) nivolumab + ipilimumab + 2 cycles of chemotherapy (NIC) in the US

    Biological: nivolumab + ipilimumab

Interventions

06

What researchers measure

Primary outcomes

  1. Participant baseline socio-demographics

    Time frame: Baseline

  2. Participant baseline clinical characteristics

    Time frame: Baseline

  3. Participant treatment history

    Time frame: Baseline

  4. Treatment start and stop dates

    Time frame: Up to 6-months

  5. Reasons for 1L treatment selection

    Time frame: Day 1

  6. Initial 1L NIC treatment dose received

    NIC = first-line (1L) nivolumab + ipilimumab + 2 cycles of chemotherapy

    Time frame: Day 1

  7. Type of chemotherapy received as part of NIC treatment

    NIC = first-line (1L) nivolumab + ipilimumab + 2 cycles of chemotherapy

    Time frame: Day 1

  8. Participant NIC treatment chemotherapy schedule

    NIC = first-line (1L) nivolumab + ipilimumab + 2 cycles of chemotherapy

    Time frame: Day 1

  9. Number of NIC treatment interruptions

    NIC = first-line (1L) nivolumab + ipilimumab + 2 cycles of chemotherapy

    Time frame: Up to 6-months

  10. Date(s) of NIC treatment interruptions

    NIC = first-line (1L) nivolumab + ipilimumab + 2 cycles of chemotherapy

    Time frame: Up to 6-months

  11. Reasons for NIC treatment interruptions

    NIC = first-line (1L) nivolumab + ipilimumab + 2 cycles of chemotherapy

    Time frame: Up to 6-months

  12. Length of NIC treatment delay/interruption

    NIC = first-line (1L) nivolumab + ipilimumab + 2 cycles of chemotherapy

    Time frame: Up to 6-months

  13. Reasons for NIC treatment discontinuation

    NIC = first-line (1L) nivolumab + ipilimumab + 2 cycles of chemotherapy

    Time frame: Up to 6-months

  14. Type of 2L treatment received

    Time frame: Up to 6-months

  15. Reasons for not initiating 2L treatment

    Time frame: Up to 6-months

  16. Start and stop dates of 2L treatment initiation

    Time frame: Up to 6-months

07

Study locations

1 site
  • Cardinal Health
    Dublin, Ohio 43017, United States
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Oct 2024 to primary completion in Aug 2026, 22 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 5, 2026: primary completion Jun 2025 → Aug 2026 and completion Jun 2025 → Aug 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 9, 2025
First posted
Jun 17, 2025
StartActual
Oct 24, 2024
Primary completionActual
Aug 28, 2026was Jun 2025
CompletionActual
Aug 28, 2026was Jun 2025
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Nov 5, 2026
Primary completion
Jun 30, 2025→Aug 28, 2026 (actual)
Nov 5, 2026
Study completion
Jun 30, 2025→Aug 28, 2026 (actual)
Nov 5, 2026
Enrollment
100 (estimated)→103 (actual)
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    Active, not recruiting→Completed
    Primary completion Jun 30, 2025→Aug 28, 2026 (now actual)
    Study completion Jun 30, 2025→Aug 28, 2026 (now actual)
    Enrollment 100 (estimated)→103 (actual)
    + 2 other changes: index terms and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07024862
Responsible party
Sponsor
First posted
Jun 17, 2025
Start date
Oct 24, 2024
Primary completion
Aug 28, 2026
Completion
Aug 28, 2026
Last update
Nov 5, 2026

Study contacts

Bristol Myers Squibb Squibb
study director · Bristol-Myers Squibb

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion